Compare Zillow Group Inc Class C (Z) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Zillow Group Inc Class C vs Zoetis Inc — how do they compare? Zillow Group Inc Class C trades at $28.9 (market cap $6.59B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 4.6× Zillow Group Inc Class C's market cap, and Zoetis Inc pays a 2.9% dividend while Zillow Group Inc Class C pays none. Which is the better fit depends on your goals — on Pluang, investors hold Zillow Group Inc Class C for 38 Days and Zoetis Inc for 70 Days on average.
| Z | ZTS | |
|---|---|---|
Market Cap | $6.59B | $30.20B |
Volume | 9,134,294 | 6,175,327 |
Sector | Media | Health |
52-Week High | $78.04 | $147.53 |
52-Week Low | $27.13 | $69.09 |
Typical Hold Time | 38 Days | 70 Days |
Enterprise Value | $6.47B | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Zillow Group (Z) trades at $28.84, up 5.72% in the last session, showing strong momentum despite mixed technical signals. The company has demonstrated improving fundamentals with revenue growing from $2.2B in 2024 to $2.6B in 2025, turning a net loss of $112M into a $23M profit. Recent earnings show beats in Q1 and Q2 2026, though Q4 2025 missed expectations. Analyst sentiment is divided with a $60.33 consensus price target representing significant upside potential from current levels.
Zillow presents a compelling growth story with improving profitability and strong analyst targets, but faces headwinds from housing market volatility and rising mortgage rates. The stock's high P/E ratio of 126.83 reflects growth expectations, while technical indicators show conflicting signals with bullish overall momentum but bearish moving averages. The resolution of the FTC lawsuit removes regulatory overhang, but competition with Compass and market sensitivity to interest rates remain key risks.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
